Healthcare, Pharma & Life Sciences

Amsterdam – October 29, 2026 -- Lapsi Health, the Dutch clinical AI company behind the Keikku platform, has appointed Fabia Tetteroo-Bueno, former Senior Vice President and General Manager of Philips Latin America, to its Board of Directors. She will guide Lapsi's strategy and partnerships as Keikku scales across the region.

First woman to lead Philips in Latin America joins the board

Born in Brazil, Tetteroo-Bueno built her career across three continents at Royal Philips. In 2020 she became head of Philips Latin America, the first woman to lead the company in the region, and steered its healthcare strategy through the COVID-19 pandemic. She later held senior global commercial roles, including Head of Global Sales for the Software business.

MILWAUKEE – October 29, 2026 -- The Society for Immunotherapy of Cancer (SITC) received almost 1,200 abstract submissions for 2026 and will showcase eight selected studies at a virtual press briefing on Wednesday, Nov. 4, from 12 to 1:30 p.m. MT.

SITC publishes accepted late-breaking abstracts ahead of its 41st Annual Meeting

The society has released titles and authors for the accepted Late-breaking Abstracts, which contain new data from interventional clinical trials in humans. They will be presented at the 41st Annual Meeting & Pre-Conference Programs, held Nov. 4-8, 2026, in Phoenix, AZ, and virtually.

Briefing lineup spans cell therapies, oncolytic viruses and a PD-1/VEGF bispecific

Eight presentations are scheduled, in this order:

BRANFORD, CT – October 29, 2026 -- Urologic Design closed an oversubscribed $1.2 million pre-seed round to move its patented urinary incontinence device toward a first-in-human study.

Angel Investor Forum leads a syndicate of regional and university-linked backers

Angel Investor Forum, described as Connecticut's primary angel group, led the equity round. HBS Alumni Angels of Boston, Haven Founders Fund, Connecticut Innovations and Yale Angels joined, along with several individual investors.

Matthew Stannard, Life Sciences Lead at Angel Investor Forum, said the firm backed the company because it bridges the gap between absorbent products and surgery. He called first-in-human testing "an important step on the path to commercialization."

Berlin – October 29, 2026 -- Germany's pharmacist federation ABDA is lobbying the Bundesrat to retain the pharmacy-only dispensing requirement. It argues that the emergency care reform passed by the Bundestag on October 15 would let physicians dispense medicines directly and weaken drug safety checks.

Reform allows doctors to dispense drugs in emergency centers and out-of-hours services

The Notfallversorgungsreformgesetz would let physicians hand medicines directly to patients, for example in Integrated Emergency Centers and ambulatory emergency services. ABDA President Thomas Preis says this circumvents the pharmacy obligation, which protects patients from medication errors and misuse.

Preis describes the established pharmacist-physician four-eyes principle as a central safeguard. He says pharmacists are the last control point before a drug is dispensed, responsible for correct intake and dosage.

MIAMI BEACH – October 29, 2026 -- USA Sports Medicine has appointed Michael Holland, a healthcare finance executive with almost 30 years of experience, as President and Chief Financial Officer to steer capital strategy for its 25-location Florida network.

Holland will work alongside founder and CEO Dr. Matthew Cooper and VP Kevin Mills. His remit covers financial strategy, infrastructure, strategic partnerships and entry into new markets.

Palm Beach County adds five clinics in 2026

The Miami-based operator opened five locations in Palm Beach County this year. Holland said the sites are already exceptionally busy. The company also runs clinics inside private clubs, luxury residential communities and fitness destinations across Miami-Dade, Broward and Palm Beach counties.

Cooper described the mandate as ensuring the business behind the brand is built to grow for decades.

Burlington – October 29, 2026 -- The U.S. Food and Drug Administration has approved an expanded indication for Instylla's Embrace Hydrogel Embolic System (HES), covering embolization of peripheral arterial bleeds in vessels of 6 mm or less. Embrace HES is now the first and only liquid embolic approved for both peripheral arterial bleeds and hypervascular tumors, according to the privately held company. The product is commercially available in the U.S.

HALT trial met both primary endpoints in 130 patients

The approval rests on the HALT study, a prospective, multicenter, single-arm trial that enrolled 130 patients with peripheral arterial bleeds at 22 U.S. sites. Embrace HES delivered 100% freedom from major adverse events and 90.0% clinical success, defined as no rebleeding from the target lesion, through 30 days. Both were prespecified primary endpoints.

Weihai, China – October 29, 2026 -- Nine of the 20 labelers in the FDA's GUDID database for topical tissue adhesives hold no clearance of their own, yet they account for 44 of 97 device records (45%), according to a September 2026 supplier-landscape report from VEMERIX, the international brand of Weihai Medison Medical Equipment Co., Ltd. The company has distilled the findings into a document checklist for buyers sourcing medical cyanoacrylate adhesives in bulk.

US clearances concentrate in 14 applicant groups, four of which hold 23 of 36

The report counts 36 FDA 510(k) clearances under product code MPN (topical tissue adhesives) between December 2008 and September 2025. Four companies hold 23 of them. The 45% figure reflects lawful private-label and relabeling arrangements, through which much of the category reaches the market, and describes traceability rather than compliance.

Monterey – October 29, 2026 -- LanguageLine's AI Translation App has received an Innovative Technology designation from Vizient, a status that may open contract opportunities outside the traditional competitive bid process with a membership base representing about $156 billion in annual purchasing volume.

Vizient provider groups recommended the app after in-depth evaluations

LanguageLine showed the app at the Vizient Innovative Technology Exchange in Las Vegas on September 24. Vizient provider groups then ran in-depth evaluations and recommended it for the designation, citing its potential to deliver value and drive innovation across healthcare organizations.

Under the Innovative Technology Program, experts on Vizient's client-led councils assess selected products for their ability to improve clinical care, enhance patient and workforce safety, and strengthen operational performance.

Thousand Oaks – – October 29, 2026 -- Amgen (NASDAQ:AMGN) will report its third quarter 2026 financial results on Tuesday, November 3, 2026, after the close of U.S. financial markets.

Amgen schedules investor call for 4:30 p.m. ET with CEO Bradway

The earnings release will be followed by a conference call with the investment community at 4:30 p.m. ET. Robert A. Bradway, chairman and chief executive officer, will participate alongside other members of Amgen's senior management team.

Amgen streams the call live and archives the webcast for at least 90 days

Live audio of the call will be broadcast over the internet and is open to news media, investors and the general public. The webcast is available through the Investors section of Amgen's website, where the Investor Relations Events Calendar lists presentation times, webcast availability and links.

Austin – October 29, 2026 -- National Veterinary Associates (NVA) Vice President of Science and Clinical Advancement Tracy Hill, DVM, PhD, DACVIM (SAIM), has been named to Morris Animal Foundation's FY27 Feline Scientific Advisory Board (SAB). The appointment extends her clinical research work beyond NVA's network of more than 1,200 general practice, specialty and emergency veterinary hospitals.

Hill will review and score feline health grant proposals

As a board member, Hill will review and score grant proposals so that Morris Animal Foundation can identify scientifically rigorous, humane research with the potential to advance feline health and welfare. Expert review directs research funding toward studies that address knowledge gaps and ultimately inform veterinary care.